Yaron Daniely has called time on his time at HUJ’s Yissum and the Israel Technology Transfer Organization to join biotech-focused VC vehicle aMoon.
Yaron Daniely (pictured) has moved on from tech transfer umbrella board Israel Technology Transfer Organization (ITTN) and Hebrew University of Jerusalem (HUJ)’s tech transfer office Yissum.
Daniely left both organisations to join life sciences-focused VC vehicle aFund earlier this month, heading up an internal unit tasked with capitalising aMoon’s talent and scale.
Daniely had been appointed president and CEO of Yissum in June 2017 before adding the co-chairman position at ITTN in December last year.
During his time at Yissum, Daniely helped introduce a new industry-friendly tech transfer initiative, opening up almost 70 HUJ technologies under pre-prepared licence agreements drafted alongside Israel-based law firms.
Daniely’s earlier career highlights include more than eight years leading the bio-MBA program at the College of Management Academic Studies from 2010 until June 2018.
He also spent nearly seven and a half years at CNS disorder drug developer Alcobra as president and CEO from 2010 until 2017 and as board chairman for a five-month spell in mid-2017.
Daniely was director of rare disease therapy company Bioblast from 2012 until 2014, after helming single-molecule imaging system creator NanoCyte as CEO from late-2007 until 2010.
He served as cell and immune therapy developer Gamida Cell’s vice-president for business development from 2003 until 2007, having previously obtained a postdoctoral fellowship from the American Cancer Society in 2000.
Daniely’s new employer reportedly closed its second $660m VC vehicle in March 2019 with limited partners including financial service firm Credit Suisse.
The fund enters late-stage health tech deals and builds on an initial $200m vehicle unveiled by aMoon in 2018, according to Globes.
